ASH 2025 – BeOne assuages sonrotoclax safety concerns
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
ASH 2025 preview – toxicity worries hit BeOne’s sonrotoclax
The project has priority review, but deaths could raise eyebrows.
Ziihera bags a gastric win
But Enhertu is coming.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
